![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, April 17, 2019 9:00:50 AM
PR Newswire PR Newswire•April 17, 2019
SAN JOSE, Calif., April 17, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that the United States Patent and Trademark Office ("USPTO") has issued US Patent No. 10,259,855. This is the first patent covering Anixa's CAR-T cancer treatment technology.
Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)
Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)
More
The patent is titled "METHODS AND COMPOSITIONS FOR TREATING CANCER," and the inventors are Drs. Jose Conejo-Garcia and Alfredo Perales-Puchalt. Dr. Conejo-Garcia is the Chair of the Department of Immunology at Moffitt Cancer Center and Dr. Perales-Puchalt is a Senior Postdoctoral Fellow in The Wistar Institute's Vaccine & Immunotherapy Center. The patent is assigned to The Wistar Institute and Anixa Biosciences' majority-owned subsidiary, Certainty Therapeutics, Inc. is the exclusive, world-wide licensee.
Dr. Amit Kumar, Anixa's Chairman, President and CEO, stated, "The claims of this patent were allowed in January of this year as noted in a previous announcement, and we are pleased that this key patent has now issued. Those interested in reviewing the patent can now read the content." Dr. Kumar continued, "This technology takes advantage of specific hormone–hormone receptor biology to address malignancies and may hold promise to be the one of the first successful CAR-T therapies against solid tumors. While our initial focus is the treatment of ovarian cancer, the technology covered by the patent is broad and may also be effective in treating other solid tumors by exploiting an anti-angiogenesis mechanism of action. Anixa and its research and clinical development partner, the Moffitt Cancer Center, hope to file an IND application for this therapy later this year.
Recent ANIX News
- Anixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine Technology • PR Newswire (US) • 07/17/2024 12:00:00 PM
- Anixa Biosciences Announces $5 Million Share Repurchase Program • PR Newswire (US) • 07/15/2024 12:30:00 PM
- Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial • PR Newswire (US) • 06/24/2024 12:45:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 01:22:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 01:56:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 03:18:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/10/2024 02:03:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 04:24:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 02:57:50 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 06/04/2024 09:00:57 PM
- Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial • PR Newswire (US) • 05/21/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 12:35:37 PM
- Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines • PR Newswire (US) • 05/08/2024 12:25:00 PM
- Anixa Biosciences CEO Featured on "Target: Cancer Podcast" by Oncologist Dr. Sanjay Juneja • PR Newswire (US) • 05/06/2024 12:05:00 PM
- Anixa Biosciences to Participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024 • PR Newswire (US) • 04/30/2024 11:45:00 AM
- Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board • PR Newswire (US) • 04/18/2024 12:20:00 PM
- Anixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties • PR Newswire (US) • 03/14/2024 12:45:00 PM
- Anixa Biosciences Announces Presentation at 24th Annual World Vaccine Congress • PR Newswire (US) • 03/11/2024 12:00:00 PM
- Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial • PR Newswire (US) • 02/12/2024 12:30:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/08/2024 09:15:32 PM
- Anixa Biosciences Announces Participation in 2024 NeauxCancer Oncology Conference • PR Newswire (US) • 01/29/2024 01:50:00 PM
- Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology • PR Newswire (US) • 01/23/2024 12:55:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 12:08:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 12:07:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 12:07:08 AM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM
HealthLynked Expands Telemedicine Nationwide • HLYK • Jul 17, 2024 8:00 AM
Peer To Peer Network aka Mobicard™ Launches AI Investor Chatbot Boosting Engagement & Lead Generation on Ihub • PTOP • Jul 15, 2024 8:30 AM
Greenlite Ventures Announces AI Integration into No Limit Platforms • GRNL • Jul 15, 2024 8:00 AM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM